S&P 500 cuts losses as Nvidia climbs ahead of results
Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a $1.47 billion market cap biotech company, saw its General Counsel John R. Moore sell 2,098 shares of common stock on August 12, 2025, at an average price of $13.3924, for a total value of $28,097. The transaction occurred as the stock showed recent momentum, gaining 7.57% over the past week, though still down 45% over six months. Prices ranged from $13.36 to $13.49, with analysts setting targets between $14 and $51.
On the same day, Moore also exercised options to acquire 5,781 shares of Edgewise Therapeutics common stock at a price of $0. Additionally, Moore acquired 26,875 restricted stock units and options to purchase 161,250 shares of common stock. According to InvestingPro, the company maintains strong financial health with more cash than debt and high liquidity ratios, though it’s currently not profitable. For deeper insights into insider trading patterns and comprehensive financial analysis, explore the detailed Pro Research Report available on InvestingPro.
In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025, with a loss of $0.34 per share compared to analysts’ projections of a $0.42 loss. The company also maintained a robust cash position of approximately $594 million as of June 30, 2025, which supports its ongoing clinical programs. RBC Capital responded to these earnings by raising its price target for Edgewise Therapeutics to $49, maintaining an Outperform rating. Raymond James also reiterated its Strong Buy rating with a $46 price target after the company’s financial results and corporate update. Both firms noted that key catalysts for Edgewise Therapeutics are on track, including the EDG-7500 Phase 2 CIRRUS-HCM Part D results expected in the fourth quarter of 2025. Earlier trial data showed positive efficacy signals, although there were concerns about atrial fibrillation in some patients. These developments reflect the ongoing interest and analysis from investment firms regarding Edgewise Therapeutics’ progress and financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.